Vai al contenuto principale

Dott.ssa Virginia Liberini

Contatti

Curriculum vitae

Curriculum Vitae

Attività di ricerca

Over the past ten years, advances in computer technology and the development of new diagnostic and therapeutic techniques have created significant advances in cancer care, but also new challenges. For this reason, radiomics has aroused the interest of the scientific community in recent years.

Radiomics is a field of medical study that aims to extract large amount of quantitative features from medical images using data-characterization algorithms. These features, termed radiomic features, have the potential to uncover disease characteristics that fail to be appreciated by the naked eye. The hypothesis of radiomics is that the distinctive imaging features can help to better describe the biological behavior of the disease and therefore be used in the different natural phases of the disease (staging, re-staging and evaluation of treatment response).

Radiomics is therefore born to develop decision support tools and involves the combination of data obtained from medical imaging with other patient characteristics to increase the power of decision support models. Quantitative data extracted from images can be integrated into multidisciplinary predictive models for patient management, including through the use of machine learning and artificial intelligence methods. All this with the idea of providing valuable information for personalized therapy.

Several studies have already shown great promise of radiomic for supporting clinical decision in oncology field, the problem is that these studies are very heterogeneous and the complexity of the radiomics workflow increases the need to standardize the methodological approach. In the last two years an international group has dedicated itself to this problem, stipulating two documents with procedural recommendations on the method (radiomics quality score proposed by Lambin and - IBSI - The Image Biomarker Standardization Initiative).

Based on these documents, the principle aim of my PhD project is to develop a methodological approach to the radiomic analysis of PET/CT images, repeatable and reproducible, for the study of tumor heterogeneity in different tumor models, which allows a greater understanding of the biology of the tumors, with particular attention to endocrine tumors (neuroendocrine and thyroid tumors) and prostate.

The secondary aims of this project are: - verify the presence of a correlation between the texture features identified and the prognostic indices already known or under study (clinical, laboratory and immunohistochemistry and genetics data) in different tumor models; - identify, in association with the prognostic data already known in the literature, the package of texture features which will allow to capture the tumor aggressiveness. This can help the decision process (diagnostic and therapeutic), diversifying among the different tumor clusters with different biological and clinical behavior; - identify parameters and indicators that can help and predict the response to therapy.

- Balma M. et al. The role of theragnostics in breast cancer: a systematic review of the last 12 years. In press

- Liberini V. et al. Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics. Eur Radiol Exp. 2022 Jun 15;6(1):27. doi: 10.1186/s41747-022-00282-0. PMID: 35701671; PMCID: PMC9198151.

- Ceci F. et al. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3257-3268. doi: 10.1007/s00259-022-05741-9. Epub 2022 Feb 26. PMID: 35217883; PMCID: PMC9250462.

- Balma M. et al. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. Front Med (Lausanne). 2022 Apr 12;9:881551. doi: 10.3389/fmed.2022.881551. PMID: 35492341; PMCID: PMC9039137.

- Thuillier P. et al. Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors. J Nucl Med. 2022 Jul;63(7):1014-1020. doi: 10.2967/jnumed.121.262652. Epub 2021 Nov 5. PMID: 34740949.

- Husmann L. et al. Staging of Alveolar Echinococcosis with PET/CT: Prediction of Benzimidazole Therapy Duration in Inoperable Patients. Sci Rep. 2022 Jul 6;12(1):11392. doi: 10.1038/s41598-022-15641-5. PMID: 35794149; PMCID: PMC9259695.

- Liberini V. et al. Predictive value of baseline [18F]FDG PET/CT for response to systemic therapy in patients with advanced melanoma. J Clin Med. 2021 Oct 27;10(21):4994. doi: 10.3390/jcm10214994. PMID: 34768517; PMCID: PMC8584809.

- Liberini V. et al. BSREM for brain metastases detection with [18F]FDG PET/CT in lung cancer patients. J Digit Imaging. 2022 Jun;35(3):581-593. doi: 10.1007/s10278-021-00570-y. Epub 2022 Feb 25. PMID: 35212859; PMCID: PMC9156589.

- Liberini V. et al. Histopathological Features of Parathyroid Adenoma and [18F]F-Choline Uptake in PET/MR of Primary Hyperparathyroidism. Clin Nucl Med. 2022 Feb 1;47(2):101-107. doi:10.1097/RLU.0000000000003987. PMID: 35006103.

- Liberini V. et al. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers (Basel). 2021 Sep 10;13(18):4543. doi: 10.3390/cancers13184543. PMID: 34572771; PMCID: PMC8464855.

- Messerli M. et al. Clinical evaluation of data-driven respiratory gating for PET/CT in an oncological cohort of 149 patients: impact on image quality and patient management. Br J Radiol. 2021 Oct 1;94(1126):20201350. doi: 10.1259/bjr.20201350. Epub 2021 Sep 14. PMID: 34520673.

- Liberini V. et al. Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [ 18 F]FDG PET/CT. Eur Radiol. 2021 Oct;31(10):8011-8020. doi:10.1007/s00330-021-07852-7. Epub 2021 Mar 25. PMID: 33768288.

- Liberini V. et al. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. Molecules. 2021 Apr 11;26(8):2201. doi: 10.3390/molecules26082201. PMID: 33920423; PMCID: PMC8069316.

- Thuillier P. et al. Diagnostic value of both conventional PET parameters and radiomic features extracted from 18F-FDG PET/CT for histologic subtype classification and characterization of lung neuroendocrine neoplasms. Biomedicines. 2021 Mar 10;9(3):281. doi: 10.3390/biomedicines9030281. PMID: 33801987; PMCID: PMC8001140.

- Liberini V. et al. COVID-19 and Aspiration Pneumonia: Similar Pulmonary Findings with Different Diagnoses-a Pitfall in [18F]FDG PET/CT. SN Compr Clin Med. 2021 Jul 29:1-4. doi: 10.1007/s42399-021-01030-y. Epub ahead of print. PMID: 34345767; PMCID: PMC8321507.

- Liberini V. et al. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel). 2020 Dec 12;10(12):1083. doi: 10.3390/diagnostics10121083.

- Liberini V. et al. Impact of segmentation and discretization on radiomic features in 68Ga-DOTATOC PET/CT images of neuroendocrine tumor. EJNMMI Phys. 2021 Feb 27;8(1):21. doi:10.1186/s40658-021-00367-6. PMID: 33638729; PMCID: PMC7914329.

- Liberini V. et al. 68Ga-DOTATOC PET/CT based radiomic analysis and PRRT outcome: a preliminary evaluation based on an exploratory radiomic analysis. Front Med (Lausanne). 2021 Jan 26;7:601853. doi: 10.3389/fmed.2020.601853.

- Liberini V. et al. Impact of PET data driven respiratory motion correction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS). Sci Rep 11, 2273 (2021). https://doi.org/10.1038/s41598-020-80855-4

- Nervo A. et al. Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues. J Endocrinol Invest. 2020 Aug 3. doi: 10.1007/s40618-020-01374-7.

- Polverari G. et al. 18F-FDG PET/CT Parameters and Radiomics Features Analysis in Advanced NSCLC treated with Immunotherapy as Predictors of Therapy Response and Survival. Cancers 2020, 12, 1163; doi:10.3390/cancers12051163.

- Finessi M. et al. Major limits of dosimetrically determined activities in advanced differentiated thyroid carcinoma. Q J Nucl Med Mol Imaging. 2019 Sep; 63 (3): 258-266. doi: 10.23736/S1824-4785.19.03211-4.

- Liberini V. et al. 68Ga-DOTA-TOC PET/CT: a typical case of von Hippel-Lindau disease. Clin Nucl Med. 2019 Feb; 44 (2): 125-126. doi: 10.1097/RLU.0000000000002395.

- I. Motta et al. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. J. Antimicrob Chemother, 2018 Feb 1;73(2):546-548. doi: 10.1093/jac/dkx385.

 

- Liberini V., Finessi M. et Deandreis D. (2021) A Patient with Follicular Thyroid Cancer and a Painful Bone Metastases at Risk for Pathologic Fracture. Chapter pp 275-295. Thyroid Cancer. A case-based approach. II edition. Editors: Giorgio Grani, David S. Cooper, Cosimo Durante. Springer. https://doi.org/10.1007/978-3-030-61919-0_31

- Finessi M., Liberini V. et Deandreis D. (2020) Cancer staging with 18F-FDG PET/CT in hyperglycemic patients. Chapter pp 641-654. Obesity and Diabetes. Editors: Faintuch J., Faintuch S. (eds) Springer, Cham. https://doi.org/10.1007/978-3-030-53370-0_47

 

- Liberini V. et al. Development of 3D-printed inserts for NEMA-phantom simulating necrotic tumor lesions for the evaluation of reproducibility of PET/CT radiomic features Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2022 - TROP (Top Rated Oral Presentation) Session: Radiomics - Oral Presentation. Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. Eur J Nucl Med Mol Imaging 49 (Suppl 1), 1–751 (2022). https://doi.org/10.1007/s00259-022-05924-4

- Albano D. et al. [18F]FDG PET/CT role in FUO: an Italian multicentric study Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2022. Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. Eur J Nucl Med Mol Imaging 49 (Suppl 1), 1–751 (2022). https://doi.org/10.1007/s00259-022-05924-4

- Evangelista L. et al. ITA-IMMUNO-PET: The Role Of FDG PET/CT In The Evaluation Of Response To Immunotherapy In Patient (PTS) With Lung Cancer (LG) And Malignant Melanoma (MM).Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2022. Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. Eur J Nucl Med Mol Imaging 49 (Suppl 1), 1–751 (2022).https://doi.org/10.1007/s00259-022-05924-4

- Albano D. et al. 18F-FDG PET/CT role in FUO: an Italian Multicentric Study. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Balma M. et al. Interobserver agreement of [18F]PSMA-1007 PET/CT images according to the EPSMA criteria in prostate cancer (PCA)patients with biochemical recurrence after primary surgery. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Nicolotti D.G. et al. [18F]PSMA-1007 PET/CT impact on decision-making strategiesfor prostate cancer patients with biochemical recurrence at lowPSA values after primary surgery: a retrospective preliminaryevaluation. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Buschiazzo A. et al. Monitoring treated brain neoplasms patients with 11C-MET PETand MRI: a retrospective sampling of discrepancies in evaluatingtreatment response or identifying focal relapse. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Evangelista L. et al. ITA-IMMUNO-PET: comparison between CT and FDG PET/CT in the evaluation of response to immunotherapy and their impact on the prognosis. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Bianchi A. et al. ITA-IMMUNO-PET: suspected adverse events correlatedto immunotherapy assessed by FDG PET/CT. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Evangelista L. et al. ITA-IMMUNO-PET: the prognostic role of baseline FDG PET/CT in patients candidates to immunotherapy. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- De Rimini M.L. et al. ITA-IMMUNO-PET: the role of FDG PET/CT in the evaluation of response to immunotherapy. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Laudicella R. et al. [68GA]DOTATOC PET/CT machine-learning applicationsin the prediction of response in GEP-NETS undergoing[177LU]DOTATOC PRRT: the ‘‘THERAGNOMICS’’ concept. 15th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN). Clin Transl Imaging 10 (Suppl 1), 1–111 (2022). https://doi.org/10.1007/s40336-022-00492-x

- Liberini et al. Interobserver agreement for [18F]F-PSMA-1007 PET/CT images according to the E-PSMA criteria in prostate cancer patients. Journal of Nuclear Medicine. Vol. 63, Issue supplement 2. June 1, 2022

- Liberini V. et al. Parathyroid Histopathology and [18F]F-Choline Uptake in PET/MR in Primary Hyperparathyroidism. in press. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2021 - TROP (Top Rated Oral Presentation) Session: Nuclear Medicine Imaging and Therapy in Thyroid and Parathyroid Disorders.

- Thuillier P. et al. Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors. in press. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2021 - Clinical Oncology Track – TROP (Top Rated Oral Presentation) Session: Neuroendocrine- Oral Presentation.

- Liberini V. et al. Predictive value of baseline [18F]FDG PET/CT for response to systemic therapy in patients with advanced melanomas. in press. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2021 - Clinical Oncology Track - TROP (Top Rated Oral Presentation) Session: Gynaecological and Melanoma - Oral Presentation.

- Liberini V. et al. BSREM for Brain Metastases Detection with [18F]FDG PET/CT in Lung Cancer Patients. in press. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – EAMN Annual Congress 2021 - Cutting Edge Science Track - Featured Session: PET Reconstructions and Corrections - Oral presentation.

- Thuillier P. et al. Valeur pronostique des paramètres volumétriques corps entier extraits de la TEP/TDM au 68Ga-DOTATOC dans les tumeurs neuroendocrines bien différenciées. Annales d’Endocrinologie, Volume 82, Issue 5, 2021, Page 274, ISSN 0003-4266, https://doi.org/10.1016/j.ando.2021.08.056.

- Thuillier P. et al. Valeur prédictive des paramètres volumétriques corps entier et osseux de la 18F-FDG-TEP/TDM préthérapeutique dans la réponse au Lenvatinib chez les patients traités pour un cancer différencié de la thyroïde réfractaire à l’iode. Annales d’Endocrinologie, Volume 81, Issue 4, 2020, Page 251, ISSN 0003-4266, https://doi.org/10.1016/j.ando.2020.07.293.

- Liberini V. et al. Impact of PET data driven respiratory motion correction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS). EJNMMI. September 2020; vol 47 (suppl 1): 1-753. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – Oral presentation.

- Polverari G. et al. 18F-FDG PET Parameters and Radiomics Features Analysis in Advanced NSCLC treated with Immunotherapy as Predictors of Therapy Response and Survival. EJNMMI. September 2020; vol 47 (suppl 1): 1-753. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – Oral presentation.

- Califaretti E. et al. 18F-FDG PET/CT whole body volumetric evaluation in iodine-refractory differentiated thyroid cancer as predictors of Lenvatinib response. EJNMMI. September 2020; vol 47 (suppl 1): 1-753. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – Oral presentation.

- Liberini V. et al. Peptide Receptor Radionuclide Therapy (PRRT) Putcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll? Neuroendocrinology 2020. Vol. 110 (suppl 1). Abstracts of the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease.

- Liberini V. et al. Robustness of Radiomic Features in 68Ga-DOTATOC PET/CT: A Monocentric Experience for Neuroendocrine Tumors. Neuroendocrinology 2020. Vol. 110 (suppl 1). Abstracts of the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease.

- Liberini V. et al. A Study of Radiomic Features Robustness for 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors. EJNMMI. October 2019; vol 46 (suppl 1): 1-952. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine – Oral Presentation.

- Nicolotti D. et al. Impact of late pelvic acquisition on 68Ga-PSMA-11 PET/CT positivity rate and inter-rter reliability analysis. EJNMMI. October 2019; vol 46 (suppl 1): 1-952. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine.

- Ceci F. et al. 68Ga-PSMA-11 PET/CT in hormone-naïve recurrent prostate cancer: prospective, single-center study in patients eligible for salvage therapy. EJNMMI. October 2019; vol 46 (suppl 1): 1- 952. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine.

- Ceci F. et al. Salvage radiotherapy guided by 68Ga-PSMA-11 PET/CT in patients with biochemical persistence (BCP) after radical prostatectomy for prostate cancer. EJNMMI. October 2019; vol 46 (suppl 1): 1-952. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine.

- Finessi M. et al. Comparison of 68Ga DOTATOC PET/CT with morphological imaging in staging of neuroendocrine tumors. EJNMMI. October 2019; vol 46 (suppl 1): 1-952. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine.

- Pilati E. et al. Impact of 68Ga DOTATOC PET/CT in the Therapeutic Management of Neuroendocrine Tumors. EJNMMI. October 2019; vol 46 (suppl 1): 1-952. Abstracts book of the Annual Congress of the European Association of Nuclear Medicine.

- Liberini V. et al. Can texture analysis be used for a vivo “imaging biopsy” in neuroendocrine tumors? A first step feasibility study with 68Ga-DOTATOC PET/CT. Neuroendocrinology 2019; 108 (suppl 1): I-X. Abstracts of the 16th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease.

- Pilati E. et al. Impact of 68Ga DOTATOC PET/CT in the therapeutic management of neuroendocrine tumors. Clin Transl Imaging (2019), vol 7 (Supp 1): S1-S138. AIMN XIV Annual Congress Abstract.

- Liberini V. et al. Can texture analysis be used for a vivo “imaging biopsy” in neuroendocrine tumors? A first step feasibility study with 68Ga-DOTATOC PET/CT. Clin Transl Imaging (2019), vol 7 (Supp 1): S1-S138. AIMN XIV Annual Congress Abstract – selected for highlight.

- Liberini V. et al. A strange case of multiple fractures: a case report. Clin Transl Imaging (2017), vol 5 (Suppl 1): S1–S153. AIMN XIII Annual Congress Abstract.

- Liberini V. et al. The role of lymphoscintigraphy in the diagnosis of lymphocele after renal transplant: a case report. Clin Transl Imaging (2017), vol 5 (Suppl 1): S1–S153. AIMN XIII Annual Congress Abstract.

- Balma M. et al. The role of 123I-FP- CIT SPECT in the study of the serotonergic system in amyotrophic lateral sclerosis: a potential aid in understanding etiopathogenesis. Clin Transl Imaging (2017), vol 5 (Suppl 1): S1–S153. AIMN XIII Annual Congress Abstract.

- Galati A. et al. FP- CIT gender differences. Removing the background to focus on the target. Clin Transl Imaging (2017), vol 5 (Suppl 1): S1–S153. AIMN XIII Annual Congress Abstract.

 

- 01-23 March 2021 - Teacher as collaborator of Prof. D. Deandreis
Subject: RESEARCH 4 (Research Implementation)
Course title: [f007-c205] laurea spec. in scienze delle professioni sanitarie tecniche diagnostics - in Turin)
Organiser: University of Turin (address: ateneo@pec.unito.it)
N. 10,00 teaching hours
https://diagnostiche.campusnet.unito.it/do/corsi.pl/Show?_id=fqz8

 

- 11th – 14th June 2022 “SNMMI 2022 Annual Meeting. Vancouver, BC, Canada” - Web conference

- 1st – 2nd April 2022 “ProsTIC Preceptorship 2022 – Melbourne, Australia” - Web conference

- 12th – 15th May 2022 "XV National Annual Congress - Associazione Italiana di Medicina Nucleare ed Imaging Molecolare (AIMN)" - Turin, Italy – Conference speaker

- 20th – 23th October 2021 “Annual Congress of the European Association of Nuclear Medicine EANM” – Web conference

- 01th July 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione FDG vs FET oncologica”

- 28th June 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione FDG”

- 24th June 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione DAT-DOPA”

- 21th June 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione Amiloide”

- 11th May 2021. AIMN Webinar “PSMA-PET nel cancro della prostata”

- 21th June 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione Amiloide”

- 24th June 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione DAT-DOPA”

- 28th June 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione FDG”

- 01th July 2021. AIMN Webinar “THE POWER OF FUNCTIONAL THINKING – Refertazione FDG vs FET oncologica”

- 20th – 23th October 2021 “Annual Congress of the European Association of Nuclear Medicine EANM” – Web conference

 

- 30th September 2019 - D-day 2019 doctoral school - Area Scienze della Vita e della Salute – UNITO.

- 29th and 30th November 2019 “PRIME Masterclass in Neuroendocrine Tumors. A multidisciplinary Interactive Workshop” Budapest, Hungary.

- 9th, 11th and 13th Dic 2019 "Bibliography and bibliometrics like pros" (Second Edition) – Doctoral School of the University of Turin – UNITO – Turin.

- 20th January 2020 “Teragnostica sfide di oggi e prospettive future” Turin, Italy.

- 30th Jan – 01th Feb 2020 “EANM FOCUS 3: Molecular Imaging and Theranostics in Neuroendocrine Tumours” EANM - Athens, Greece.

- 21th, 23th, 28th and 30th Sept 2020 "Open Science and FAIR Data" – Doctoral School of the University of Turin – UNITO – Turin.

- 31th March 2020 FAD AIMN course "Prostate cancer and the role of PSMA".

- 20th Decembr 2020 FAD AIMN course "PET imaging in the era of precision medicine: assessing response to target therapies".

- 20th Decembr 2020 FAD AIMN course "The Report in Nuclear Cardiology: the importance of communicating effectively".

- 20th Decembr 2020 FAD AIMN course "Role of nuclear medicine in infections/inflammations".

- 20th Decembr 2020 FAD AIMN course "Radiomics and Nuclear Medicine".

- 28th September – 1st October 2022 "Basic course in Nuclear Medicine in Neurology" - Intercontact Srl, Pesaro, Italy.

 

- 30th September 2019 - D-day 2019 doctoral school - Area Scienze della Vita e della Salute – UNITO.

- December 2019 Workshop "Ricerca Bibliografica - Polo Scienze della Natura" complementary research training.

- December 2019 "Bibliography and bibliometrics like pros" (Second Edition) complementary research training

- September 2020 "Open Science and FAIR Data", complementary research training

- 01th February 2021 - "Basics of project writing"

- 10-12th February 2021 - "Fundamentals and methodology of clinical research" - Roberto Passera

- 28th July 2021 - "Alteration of intestinal microbioma as organ insufficiency: a microbiological point of view" - Rossana Cavallo

- 29th July 2021 - "Lecture: Fitting regression models: interpretation of regression coefficients, uncertainty measures and hypothesis testing" - Milena Maule

- 30th August 2021 - "Pathogenesis of diabetic nephropathy" - Gabriella Gruden

- 02th September 2021 - "SGLT2-i in diabetes and beyond" - Gabriella Gruden

- 06th September 2021 - "Precision medicine in oncology" - Livio Trusolino

- 08th September 2021 - "Monogenic forms of hypertension" - Paolo Mulatero

- 13th September 2021 - "Targets for functional imaging in medicine" - Désirée Deandreis

- 27th September 2021 - "Clinical trials in oncology: Failures and successes" - Livio Trusolino

- 28th September 2021 - "Etiopathogenesis of diabetic retinopathy" - Massimo Porta

- 09th June 2022 - "Biology and Diagnosis of SARS CoV2" - Cristina Costa

- 21th July 2022 - "Alteration of intestinal microbioma as organ insufficiency: practical implications" - Francesco Giuseppe De Rosa

- 22th September 2022 - "Therapeutic strategies for liver transplant" - Renato Romagnoli

 

- The ENETS CoE Training Fellowship 2019 - May 2019 - Aug 2019 - Department of Nuclear Medicine - University Hospital of Zurich – Zurich, Switzerland - Chair Prof. P. A. Kaufmann;

- Researcher - Nuclear Medicine Department of University of Zurich - Sept 2020 – Nov 2020 - Department of Nuclear Medicine - University Hospital of Zurich – Zurich, Switzerland - Chair Prof. P. A. Kaufmann

 

Pubblicazioni

Tutti i miei prodotti della ricerca
Ultimo aggiornamento: 19/10/2022 12:20
Non cliccare qui!